Principal Securities, Inc. Centessa Pharmaceuticals PLC Transaction History
Principal Securities, Inc.
- $5.32 Trillion
- Q2 2025
A detailed history of Principal Securities, Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Principal Securities, Inc. holds 17 shares of CNTA stock, worth $379. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17Holding current value
$379% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CNTA
# of Institutions
127Shares Held
122MCall Options Held
638KPut Options Held
146K-
Medicxi Ventures Management (Jersey) LTD20MShares$445 Million74.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$222 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$216 Million4.43% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.4MShares$187 Million0.2% of portfolio
-
Janus Henderson Group PLC London, X06.53MShares$146 Million0.04% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $2.1B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...